BIORESTORATIVE THERAPIES INC (BRTX)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$1.510.00%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
QuarterlyIQ Insights · BRTX
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 354.3% |
| Our one-year growth estimate | diamond | 36.4% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-05.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 318.0 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Elevated risk of a next-quarter earnings miss: this name is a smaller-cap name (higher miss base rate) and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Model as of 2026-11-05 · Compared with 117 industry peers
BRTX — legal / regulatory event — Changes in Registrant’s Certifying Accountant
Dated 2026-09-10
Changes in Registrant’s Certifying Accountant. Dismissal of CBIZ CPAs P.C. On August 28, 2026, BioRestorative Therapies, Inc. (the “Company”) dismissed CBIZ CPAs P.C. (“CBIZ”) as the Company’s independent registered public accounting firm, effective as of that date. The decision to change independent registered public accounting firms was approved by the Board of Directors of the Company (the “Board”) on August 26, 2026 and approved and ratified by the Audit Committee of the Board on Septembe…
Why it matters: BRTX missed the filing deadline for its June 2026 quarter. A timely report can show that filing is back on track.
Watch forThe company files its June 2026 Form 10-Q and its next required report by the due date.
Also watch forThe June 2026 Form 10-Q remains unfiled, or another required report is late.
Why it matters: Revenue rose from $11,800 in 2025-Q3 to $23,170 in 2026-Q1, but remains small. More growth would show progress on revenue generation.
Supportive ifQuarterly revenue exceeds $23,170 in the next reported quarter and rises year over year.
Worry ifQuarterly revenue falls below $23,170 or declines year over year in the next report.
Why it matters: Operating losses improved to $3.39 million in 2026-Q1. A further drop would show continued progress on costs.
Supportive ifThe next reported operating loss is less than $3.39 million.
Worry ifThe next reported operating loss is $3.39 million or more.
Why it matters: BRTX dismissed CBIZ as its auditor. The next filing can show whether a new firm is in place and whether the company reports any audit issues.
Watch forA filing names a new independent auditor. It reports no open audit issue or delay.
Also watch forA filing reports no new auditor, a late audit, or an open audit issue.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$270 on $10,000 · ±2.7% | How much price usually moves either way. |
| Bad day | $1,184 loss on $10,000 · 11.8% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $9,534 loss on $10,000 · 95.3% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: The split aimed to regain Nasdaq's $1.00 minimum bid-price rule. Staying above $1.00 and meeting other listing rules would address this risk.
Watch forA company filing says Nasdaq confirmed compliance, with the bid price at or above $1.00 and no other listing breach.
Also watch forNasdaq issues a new bid-price or other listing notice, or the share price falls below $1.00 and compliance is lost.
Why it matters: The loan may help fund operations, but the stated amount is up to $1 million. A filing can show how much BRTX draws and whether funds arrive.
Watch forA filing confirms BRTX drew funds under the Bowery loan and reports cash received.
Also watch forA filing shows no loan draw, or states the loan was ended or could not provide funds.